Provided by Tiger Trade Technology Pte. Ltd.

Sangamo Therapeutics, Inc.

0.0740
0.0000
Volume:- -
Turnover:- -
Market Cap:30.66M
PE:-0.19
High:0.0740
Open:0.0740
Low:0.0740
Close:0.0740
52wk High:0.7660
52wk Low:0.0637
Shares:414.29M
Float Shares:311.00M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3824
EPS(LYR):-0.4400
ROE:-2891.84%
ROA:-94.37%
PB:-1.62
PE(LYR):-0.17

Loading ...

Sangamo amends 8-K to file asset purchase agreement exhibits

Reuters
·
Jun 24

Sangamo Bankruptcy Puts Gene Therapy Platforms In Play, Eli Lilly And Astellas Circle

Benzinga_recent_news
·
Jun 24

Sangamo Therapeutics - Eli Lilly to Buy Sangamo Assets for $50 Mln Plus Assumption of Liabilities - SEC Filing

THOMSON REUTERS
·
Jun 23

Sangamo Therapeutics: Expects Restructuring to Result in Elimination of About 51 Roles in United States, or About 40% of Company's Workforce

THOMSON REUTERS
·
Jun 23

Sangamo Therapeutics: Astellas to Buy Co's Assets for $25 Mln Payable at Closing Plus up to Extra $25 Mln Payable on Achievement of Some Milestones

THOMSON REUTERS
·
Jun 23

Sangamo lines up up to $30 million debtor-in-possession loan from Northridge ATM amid Chapter 11 filing

Reuters
·
Jun 23

Sangamo Therapeutics files for Chapter 11 as Lilly, Astellas anchor asset sale bids

Reuters
·
Jun 23

Sangamo Therapeutics - St-503, Giroctocogene Fitelparvovec, and Cell Therapy Assets Remain Available for Bidders

THOMSON REUTERS
·
Jun 23

Sangamo Therapeutics - Commences Voluntary Chapter 11 Proceedings for Reorganization and Asset Auction

THOMSON REUTERS
·
Jun 23

Sangamo Therapeutics Enters Into Asset Sale Agreements With Lilly and Astellas

THOMSON REUTERS
·
Jun 23

Sangamo Therapeutics - Lilly and Astellas to Serve as Stalking Horse Bidders for Asset Sales

THOMSON REUTERS
·
Jun 23

Sangamo Therapeutics - Secures Dip Financing Commitment From Northridge Atm

THOMSON REUTERS
·
Jun 23

Sangamo Therapeutics Announces Exploration of Strategic Alternatives to Maximize Value for Stakeholders

THOMSON REUTERS
·
Jun 08

Sangamo price target lowered to $5 from $10 at H.C. Wainwright

TIPRANKS
·
May 26

Sangamo publishes corporate presentation on neurology genomic medicine platform, Fabry gene therapy

Reuters
·
May 15

Sangamo Therapeutics posts ST-503 nonclinical safety presentation for small fiber neuropathy

Reuters
·
May 12

Sangamo Therapeutics publishes ST-506 nonhuman primate brain presentation

Reuters
·
May 12

Sangamo publishes TRAC locus modular integrase retargeting presentation

Reuters
·
May 12

Sangamo Therapeutics begins trading on OTCQB Venture Market under SGMO

Reuters
·
May 11

Sangamo presents neurology epigenetic regulation data at ASGCT annual meeting

Reuters
·
Apr 30